Fractyl Health Announces 6-Month REMAIN-1 Data Supporting Durability of Revita Weight Maintenance Therapy

Fractyl Health announced 6-month randomized REMAIN-1 midpoint data showing durable weight maintenance with Revita after GLP-1 discontinuation. Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings compared to sham. Patients with above median GLP-1-associated weight loss experienced ~70% less post-GLP-1 weight regain with Revita. The results support the pivotal study design and further substantiate Revita's potential as a durable procedural therapy for post-GLP-1 weight maintenance. Topline 6-month pivotal data and potential FDA filing are expected in H2 2026.